Please wait while the formulary information is being retrieved.
ARANESP (IN POLYSORBATE) (darbepoetin alfa in polysorbate 80)
- anemia due to chemotherapy and radiotherapy combination
- anemia from chemotherapy
- anemia in chronic kidney disease
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- None
ARANESP (IN POLYSORBATE) (darbepoetin alfa in polysorbate 80)
- anemia due to chemotherapy and radiotherapy combination
- anemia from chemotherapy
- anemia in chronic kidney disease
- None
- None
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Discuss the risks and benefits of darbepoetin alfa with your doctor, as this medication may rarely cause very serious (possibly fatal) side effects, including blood clots, heart attack, stroke, or heart failure. It is very important to keep all lab appointments since your doctor will need to carefully check your red blood cell count and hemoglobin level. The lowest effective dose of this medication should be used.<br /><br /> When used to treat anemia related to cancer, darbepoetin alfa may also increase the risk of death and/or cause your tumor to grow faster. This medication should be stopped after completing a treatment course of chemotherapy as directed by your doctor.
Formulary Reference Tool